Clinical trials: Liver Inflammation
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) with or without ribavirin (RBV) for 12 weeks in adults with…
- Trial name
- NCT02996682
- Testing
- SOF/VEL, RBV
- Where
- 33 sites in Japan
- Volunteers
- 102 people
- Sponsor
- Gilead Sciences
Genotype 1 Chronic Hepatitis C
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection
The GI-5005 therapeutic vaccine in combination with standard of care or standard of care alone will be injected under the skin of HCV subjects.
- Trial name
- NCT00606086
- Testing
- GI-5005, Pegylated Interferon and Ribavirin
- Where
- 25 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlobeImmune
Chronic Hepatitis B
A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B
A multicenter, randomized, open, parallel-designed Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.
- Trial name
- NCT06425341
- Testing
- HRS-5635 Injection, HRS-5635 Injection (low dose) and Peg-IFN-α, HRS-5635 Injection (high dose) and Peg-IFN-α
- Where
- China
- Volunteers
- 369 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Hepatitis C
An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
This noninterventional, open-label study will observe the safety and tolerability of peginterferon alfa-2a in combination with ribavirin among Austrian participants treated for HCV infection according to routine practice.
- Trial name
- NCT02515279
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- Austria
- Volunteers
- 463 people
- Sponsor
- Hoffmann-La Roche
HCV Infection
Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
Study of ABT-267 in both healthy volunteers and Hepatitis C virus (HCV) genotype 1 infected subjects.
- Trial name
- NCT01181427
- Testing
- ABT-267, Blood Sample Collection, Cytochrome P450 inhibitor
- Where
- 3 sites in United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Abbott
Chronic Hepatitis B
A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B
This study is a multi-center, randomized, prospective open-label study to assess the efficacy and safety of combination of peginterferon alfa-2b (40kD, Y-shape) and GM-CSF in interferon-naïve chronic hepatitis B patients with…
- Trial name
- NCT02332473
- Testing
- Ypeginterferon alfa-2b, Granulocyte-macrophage colony stimulating factor
- Where
- 12 sites in China
- Volunteers
- 110 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Chronic Hepatitis B
Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B
A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B
- Trial name
- NCT07709520
- Testing
- GST-HG141, GST-HG131
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
Hepatitis B
Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years
Comparison of adjuvanted hepatitis B vaccine to double dose of Engerix™-B in pre- /haemodialysis patients aged ≥15 years
- Trial name
- NCT00383227
- Testing
- Hepatitis B adjuvanted vaccine
- Volunteers
- 165 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C Genotype-1 Relapse
Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients
This is a study designed to identify a dose of NIM811 that has a good safety profile, is well tolerated when co-administered with SOC, and provides a clinically meaningful effect in viral load reduction compared to SOC alone.
- Trial name
- NCT00983060
- Testing
- NIM811
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV, Direct-Acting Antiviral Agent (DAA)-Experienced
- Trial name
- NCT02446717
- Testing
- ABT-493, ABT-530, ribavirin (RBV), ABT-493/ABT-530
- Volunteers
- 141 people
- Sponsor
- AbbVie
Chronic Hepatitis C, Hepatitis C (HCV)
Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults
A study to evaluate immune restoration following removal of viral antigen in non-cirrhotic hepatitis C virus (HCV) genotype (GT) 1a treatment-naïve and pegylated-interferon (pegIFN)/ribavirin (RBV) treatment-experienced adults…
- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1a
- Trial name
- NCT02476617
- Testing
- ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Volunteers
- 25 people
- Sponsor
- AbbVie
Hepatitis B
Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection
The primary objective of this study is to characterize the long term (ie, 96 weeks of follow up) bone safety profile of open-label tenofovir disoproxil fumarate (tenofovir DF) treatment in CHB-infected adolescents.
- Trial name
- NCT02479880
- Testing
- Tenofovir DF, DEXA Scan
- Where
- 11 sites in Belgium, France and 5 more
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Hepatitis C, Hepatitis C, Chronic
Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin
Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver…
- Trial name
- NCT00040027
- Testing
- thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- SciClone Pharmaceuticals
Hepatitis B
Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Therapy
The purpose of this study is to describe current rescue treatment pattern for nucleot(s)ide analogue (NA) resistance and assess the real-world treatment outcomes and health resources utilization of rescue treatments for drug…
- Trial name
- NAs resistance (NCT02791386)
- Where
- China
- Volunteers
- 383 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir…
- Trial name
- NCT02441283
- Testing
- ABT-493, ABT-530
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 384 people
- Sponsor
- AbbVie
Hepatitis B
Neovac 2 Burkina Faso: Impact of the Integration of Hepatitis B Birth Dose Vaccine Into the Infant Immunization Schedule
Hepatitis B virus (HBV) infection is an important global health problem, and the WHO adopted a strategy to eliminate HBV infection as a public health threat by the year 2030.
- Trial name
- NEOVAC2BK (NCT04029454)
- Testing
- birth dose vaccination against hepatitis B strategy
- Where
- 2 sites in Burkina Faso
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Hepatitis B， Chronic
Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients
A study demonstrates the non-inferiority of DA-2802 when compared with ㅍViread® in chronic hepatitis B patients
- Trial name
- NCT02967939
- Testing
- DA-2802, Viread®
- Where
- South Korea
- Volunteers
- 123 people
- Sponsor
- Dong-A ST Co., Ltd.
Hepatitis B, Acellular Pertussis
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines
The purpose of this study is to assess the safety in terms of fever (rectal temperature) higher than 39 degree Celcius (°C) and the immunogenicity in terms of antibody response following a booster vaccination with pneumococcal…
- Conditions
- Hepatitis B, Acellular Pertussis, Tetanus, Poliomyelitis
- Trial name
- NCT00463437
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Prevenar, Infanrix hexa
- Where
- 63 sites in Germany, Poland and 1 more
- Volunteers
- 1,437 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Liver Cirrhosis, Hepatitis C, Chronic
Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C
Study to assess the antiviral efficacy, pharmacokinetics, and tolerability of 200 mg BILN 2061 ZW in a polyethylene glycol 400 (PEG 400: ethanol) drinking solution given orally for two days bid to patients with cirrhosis and…
- Trial name
- NCT02226939
- Testing
- BILN 2061 ZW
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C Infection
Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)
This study will assess short term safety, antiviral activity and pharmacokinetics (PK) of IDX184 in combination with Peg-interferon (Peg-IFN)/Ribavirin (RBV) in participants with hepatitis C virus (HCV) genotype (GT) 1 infection.
- Trial name
- NCT01011166
- Testing
- IDX184, Peginterferon alfa-2a (Peg-IFN), Ribavirin (RBV)
- Volunteers
- 81 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.